Skip to main content
SpringerLink
Log in

S100A8/MYD88/NF-қB: a novel pathway involved in cardiomyocyte hypertrophy driven by thyroid hormone

  • Original Article
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Recent studies have evidenced the involvement of inflammation-related pathways to the development of cardiac hypertrophy and other consequences on the cardiovascular system, including the calcium-binding protein S100A8. However, this has never been investigated in the thyroid hormone (TH)-prompted cardiac hypertrophy. Thus, we aimed to test whether S100A8 and related signaling molecules, myeloid differentiation factor-88 (MyD88) and nuclear factor kappa B (NF-қB), could be associated with the cardiomyocyte hypertrophy induced by TH. Our results demonstrate that the S100A8/MyD88/NF-қB signaling pathway is activated in cardiomyocytes following TH stimulation. The knockdown of S100A8 and MyD88 indicates the contribution of those molecules to cardiomyocyte hypertrophy in response to TH, as evaluated by cell surface area, leucine incorporation assay, and gene expression. Furthermore, S100A8 and MyD88 are crucial mediators of NF-қB activation, which is also involved in the hypertrophic growth of TH-treated cardiomyocytes. Supporting the in vitro data, the contribution of NF-қB for TH-induced cardiac hypertrophy is confirmed in vivo, by using transgenic mice with cardiomyocyte-specific suppression of NF-қB. These data identify a novel pathway regulated by TH that mediates cardiomyocyte hypertrophy. However, the potential role of this new pathway in short and long-term cardiac effects of TH remains to be further investigated.

Key messages

  • Inflammation-related signaling is activated by T3 in cardiomyocytes.

  • S100A8 and MyD88 have a crucial role in cardiomyocyte hypertrophy by T3.

  • S100A8 and MyD88 mediate NF-қB activation by T3.

  • NF-қB contributes to T3-induced cardiac hypertrophy in vitro and in vivo

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Dillmann W (2010) Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev 15:125–132

    Article  CAS  PubMed  Google Scholar 

  2. Kenessey A, Ojamaa K (2006) Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 281:20666–20672

    Article  CAS  PubMed  Google Scholar 

  3. Dahl P, Danzi S, Klein I (2008) Thyrotoxic cardiac disease. Curr Heart Fail Rep 5:170–176

    Article  PubMed  Google Scholar 

  4. Elnakish MT, Schultz EJ, Gearinger RL, Saad NS, Rastogi N, Ahmed AA, Mohler PJ, Janssen PM (2015) Differential involvement of various sources of reactive oxygen species in thyroxin-induced hemodynamic changes and contractile dysfunction of the heart and diaphragm muscles. Free Radic Biol Med 83:252–261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Weltman NY, Wang D, Redetzke RA, Gerdes AM (2012) Longstanding hyperthyroidism is associated with normal or enhanced intrinsic cardiomyocyte function despite decline in global cardiac function. PLoS One 7:e46655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML (2009) Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3β/mTOR signaling pathway. Basic Res Cardiol 104:653–667

    Article  CAS  PubMed  Google Scholar 

  7. Iordanidou A, Hadzopoulou-Cladaras M, Lazou A (2010) Non-genomic effects of thyroid hormone in adult cardiac myocytes: relevance to gene expression and cell growth. Mol Cell Biochem 340:291–300

    Article  CAS  PubMed  Google Scholar 

  8. Takano AP, Diniz GP, Barreto-Chaves ML (2013) AMPK signaling pathway is rapidly activated by T3 and regulates the cardiomyocyte growth. Mol Cell Endocrinol 376:43–50

    Article  CAS  PubMed  Google Scholar 

  9. Nemska S, Monassier L, Gassmann M, Frossard N, Tavakoli R (2016) Kinetic mRNA profiling in a rat model of left-ventricular hypertrophy reveals early expression of chemokines and their receptors. PLoS One 11:e0161273

    Article  PubMed  PubMed Central  Google Scholar 

  10. Mann DL (2015) Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 116:1254–1268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Imbalzano E, Mandraffino G, Casciaro M, Quartuccio S, Saitta A, Gangemi S (2016) Pathophysiological mechanism and therapeutic role of S100 proteins in cardiac failure: a systematic review. Heart Fail Rev 21:463–473

    Article  CAS  PubMed  Google Scholar 

  12. Foell D, Frosch M, Sorg C, Roth J (2004) Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 344:37–51

    Article  CAS  PubMed  Google Scholar 

  13. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, auto-immunity, and cancer. J Leukoc Biol 86:557–566

    Article  CAS  PubMed  Google Scholar 

  14. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, Van Zoelen MA, Nacken W, Foell D, Van Der Poll T, Sorg C et al (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13:1042–1049

    Article  CAS  PubMed  Google Scholar 

  15. Schiopu A (2013) Cotoi OS (2013) S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediat Inflamm 2013:828354

    Article  Google Scholar 

  16. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR (2008) S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 102:1239–1246

    Article  CAS  PubMed  Google Scholar 

  17. Wu Y, Li Y, Zhang C, A X, Wang Y, Cui W, Li H, Du J (2014) S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-induced cardiac inflammation and injury. Hypertension 63:1241–1250

    Article  CAS  PubMed  Google Scholar 

  18. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A (2001) Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A 98:6668–6673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gupta S, Purcell NH, Lin A, Sen S (2002) Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 159:1019–1028

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ha T, Li Y, Gao X, McMullen JR, Shioi T, Izumo S, Kelley JL, Zhao A, Haddad GE, Williams DL et al (2005) Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo. Free Radic Biol Med 39:1570–1580

    Article  CAS  PubMed  Google Scholar 

  21. Ha T, Hua F, Li Y, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, Browder IW et al (2006) Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 290:H985–H994

    Article  CAS  PubMed  Google Scholar 

  22. Li T, Wang Y, Liu C, Hu Y, Wu M, Li J, Guo L, Chen L, Chen Q, Ha T et al (2009) MyD88-dependent nuclear factor-kappaB activation is involved in fibrinogen-induced hypertrophic response of cardiomyocytes. J Hypertens 27:1084–1093

    Article  CAS  PubMed  Google Scholar 

  23. Gao W, Wang H, Zhang L, Cao Y, Bao JZ, Liu ZX, Wang LS, Yang Q, Lu X (2016) Retinol-binding protein 4 induces cardiomyocyte hypertrophy by activating TLR4/MyD88 pathway. Endocrinology 157:2282–2293

    Article  CAS  PubMed  Google Scholar 

  24. Barreto-Chaves ML, Heimann A, Krieger JE (2000) Stimulatory effect of dexamethasone on angiotensin-converting enzyme in neonatal rat cardiac myocytes. Braz J Med Biol Res 33:661–664

    Article  CAS  PubMed  Google Scholar 

  25. Watkins SJ, Borthwick GM, Arthur HM (2011) The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim 47:125–131

    Article  CAS  PubMed  Google Scholar 

  26. Brown M, McGuinness M, Wright T, Ren X, Wang Y, Boivin GP, Hahn H, Feldman AM, Jones WK (2005) Cardiac-specific blockade of NF-қB in cardiac pathophysiology: differences between acute and chronic stimuli in vivo. Am J Physiol Heart Circ Physiol 289:H466–H476

    Article  CAS  PubMed  Google Scholar 

  27. Averill MM, Kerkhoff C, Bornfeldt KE (2012) S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 32:223–229

    Article  CAS  PubMed  Google Scholar 

  28. Liu Q, Chen Y, Auger-Messier M, Molkentin JD (2012) Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 110:1077–1086

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Tsoporis JN, Marks A, Haddad A, O’Hanlon D, Jolly S, Parker TG (2005) S100A6 is a negative regulator of the induction of cardiac genes by trophic stimuli in cultured rat myocytes. Exp Cell Res 303:471–481

    Article  CAS  PubMed  Google Scholar 

  30. Schneider M, Kostin S, Strøm CC, Aplin M, Lyngbaek S, Theilade J, Grigorian M, Andersen CB, Lukanidin E, Lerche Hansen J et al (2007) S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes. Cardiovasc Res 75:40–50

    Article  CAS  PubMed  Google Scholar 

  31. Yan L, Mathew L, Chellan B, Gardner B, Earley J, Puri TS, Hofmann Bowman MA (2014) S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner. Arterioscler Thromb Vasc Biol 34:1399–1411

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wei X, Wu B, Zhao J, Zeng Z, Xuan W, Cao S, Huang X, Asakura M, Xu D, Bin J et al (2015) Myocardial hypertrophic preconditioning attenuates cardiomyocyte hypertrophy and slows progression to heart failure through upregulation of S100A8/A9. Circulation 131:1506–1517

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Rahimi F, Hsu K, Endoh Y, Geczy CL (2005) FGF-2, IL-1beta and TGF-beta regulate fibroblast expression of S100A8. FEBS J 272:2811–2827

    Article  CAS  PubMed  Google Scholar 

  34. McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, Cai H, Lord RS, Geczy CL (2005) S100A8 and S100A9 in human arterial wall: implications for atherogenesis. J Biol Chem 280:41521–41529

    Article  CAS  PubMed  Google Scholar 

  35. Gordon JW, Shaw JA, Kirshenbaum LA (2011) Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ Res 108:1122–1132

    Article  CAS  PubMed  Google Scholar 

  36. Singh MV, Swaminathan PD, Luczak ED, Kutschke W, Weiss RM, Anderson ME (2012) MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. J Mol Cell Cardiol 52:1135–1144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. O’Neill LA (2006) How Toll-like receptors signal: what we know and what we don’t know. Curr Opin Immunol 18:3–9

    Article  PubMed  Google Scholar 

  38. Singh MV, Abboud FM (2014) Toll-like receptors and hypertension. Am J Physiol Regul Integr Comp Physiol 307:R501–R504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hua F, Ha T, Ma J, Gao X, Kelley J, Williams DL, Browder IW, Kao RL, Li C (2005) Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem Biophys Res Commun 338:1118–1125

    Article  CAS  PubMed  Google Scholar 

  40. Alverdi V, Hetrick B, Joseph S, Komives EA (2014) Direct observation of a transient ternary complex during IκBα-mediated dissociation of NF-κB from DNA. Proc Natl Acad Sci U S A 111:225–230

    Article  CAS  PubMed  Google Scholar 

  41. Jones WK, Brown M, Ren X, He S, McGuinness M (2003) NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling? Cardiovasc Toxicol 3:229–254

    Article  CAS  PubMed  Google Scholar 

  42. Reale C, Iervolino A, Scudiero I, Ferravante A, D'Andrea LE, Mazzone P, Zotti T, Leonardi A, Roberto L, Zannini M et al (2016) NF-κB essential modulator (NEMO) is critical for thyroid function. J Biol Chem 291:5765–5773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, Hong JT, Min KR, Kim Y (2004) Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett 571:50–54

    Article  CAS  PubMed  Google Scholar 

  44. Hu LW, Benvenuti LA, Liberti EA, Carneiro-Ramos MS, Barreto-Chaves ML (2003) Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regul Integr Comp Physiol 285:R1473–R1480

    Article  CAS  PubMed  Google Scholar 

  45. Fujiu K, Nagai R (2014) Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol 70:64–73

    Article  CAS  PubMed  Google Scholar 

  46. Gupta S, Young D, Sen S (2005) Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289:H20–H29

    Article  CAS  PubMed  Google Scholar 

  47. Javan H, Szucsik AM, Li L, Schaaf CL, Salama ME, Selzman CH (2015) Cardiomyocyte p65 nuclear factor-κB is necessary for compensatory adaptation to pressure overload. Circ Heart Fail 8:109–118

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge that the 3M mice were generously provided by Dr. W. Keith Jones at Loyola University, Chicago. The authors also thank Marina R. Fevereiro for valuable technical assistance. This work was supported by Sao Paulo Research Foundation (FAPESP), grants #2011/23352-4, #2013/22480-4, and #2015/01166-5, and in part by the start-up funds from Texas A&M Health Science Center, College of Medicine and American Heart Association Grant-in-Aid (0835227 N) to S.G.

Author information

Authors and Affiliations

  1. Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil

    Ana Paula Cremasco Takano, Anselmo Sigari Moriscot & Maria Luiza Morais Barreto-Chaves

  2. Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil

    Carolina Demarchi Munhoz

  3. Division of Molecular Cardiology, Department of Medical Physiology, College of Medicine, Texas A & M Health Science Center and Scott & White, Central Texas Veterans Health Care System, Temple, TX, USA

    Sudhiranjan Gupta

Authors
  1. Ana Paula Cremasco Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolina Demarchi Munhoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anselmo Sigari Moriscot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sudhiranjan Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Luiza Morais Barreto-Chaves
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Luiza Morais Barreto-Chaves.

Ethics declarations

Ethical standards

The experiments were performed in accordance with NIH guidelines and were approved by the Biomedical Sciences Institute/USP Ethics Committee for Animal Research and the Institutional Animal Care and Use Committee at the Texas A&M Health Science Center and Scott & White Hospital.

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takano, A.P.C., Munhoz, C.D., Moriscot, A.S. et al. S100A8/MYD88/NF-қB: a novel pathway involved in cardiomyocyte hypertrophy driven by thyroid hormone. J Mol Med 95, 671–682 (2017). https://doi.org/10.1007/s00109-017-1511-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-017-1511-y

Keywords

Search

Navigation